Urinary Tract Agents Annual Report 2005

Questions: Discounts, Updates etc.

Pages: 151

Price (Single): £1,499

Price (Departmental): £2,999

Price (Company): £4,499

Publication Date: 2005-04-19

Order Online Now

Name:
Email:
Company Name:
Telephone:
Licence Type:
Payment Method:

People that purchased this report also purchased:

Contact LeadDiscovery

If you have questions about this report
To find out if you qualify for a discount
Want a more up to date version
Can't find a report that meets your needs

Search all reports

Urinary tract agents (UTAs) are simply drugs used to treat disorders of the urinary tract. They do not treat infections of the urinary tract (UTIs) as some antibiotics do, but these drugs may provide relief from the symptoms of a UTI.

There are primarily only two diseases which are fundamental to this market:

Benign Prostatic Hyperplasia (BPH)
Overactive Bladder (OAB)

The other two disease states for which there are drugs available but the markets for which are small but will grow over the forecast period are:

Urinary incontinence
Acute urinary retention

And in 2003-2004, only five drugs dominated the UTA market:

Flomax (Boehringer Ingelheim)
Harnal (Astellas)
Detrol (Pfizer)
Proscar (Merck)
Xatral (Sanofi-Aventis)

However, considering there are only 5 drugs treating 2 diseases the total world market was in 2004 according to visiongain worth nearly $4bn, and with a staggering growth of 24.5% from 2003. This market is growing fast.

By 2010 visiongain estimates that the market could grow as high as $7bn with a very healthy CAGR of over 11%. This is a market with an exceedingly high potential.

What is driving this market?:

UTA Drugs that are likely to have alternative indications, including the highly neglected market of stress urinary incontinence
Aging population, more men getting older leading to rapidly increasing numbers of men with Benign Prostatic Hyperplasia (BPH)
Also, the incidence and prevalence of these and other urinary disorders is remarkably high, and the pipeline for new UTAs is rich, causing the market for UTAs to have this tremendously high potential.

Why you must buy this report?

This report focuses on marketed and in-development products with primary indications for urinary tract disorders. It represents a key tool for companies wishing to enter into or expand in the urinary tract agent market. The reader will be left with a clear idea of therapeutic targets currently being developed for the treatment of urinary tract disorders, who is responsible for this development and the competition that companies will face on both a pharmacological and a corporate basis. Visiongains, Urinary Tract Agents 2005 report, will answer all your questions and more. This report is indispensable.

This report will answer the following key questions for the reader:

How much was the UTA market worth in 2004
Who are the key players in the market in terms of drug brands, classes, indications and companies?
What are Urinary Tract Disorders, who do they affect and how prevalent are they?
What are the treatment options available for Urinary Tract Disorders?
What are the unmet needs in the UTA market?
What therapies are emerging for urinary tract agents and how will these affect the market?
What will each UTA on the market be worth between 2004 and 2010?
Reliable revenue forecasts for 2005-2010 using the visiongain model of forecasting
What will be the leading drugs, classes, indications and companies by 2010?

This is a fast developing market and company who has a pipeline product and thinking of entering this market must buy this report.

1. Executive Summary
- 1.1 The Market for Urinary Tract Agents will More Than Double Between 2004 and 2010
- 1.2 Aims, Scope and Format of this Report

Introduction

3. Urinary Incontinence Overview
- 3.1 What is Urinary Incontinence?
- 3.2 What is Overactive Bladder (OAB)?
- 3.3 How Does the Normal Adult Body Control Urination?
- 3.4 What Types of Urinary Incontinence are There?
  - 3.4.1 Stress Incontinence
  - 3.4.2 Urge Incontinence
  - 3.4.3 Mixed Incontinence
  - 3.4.4 Overflow Incontinence
  - 3.4.5 Reflex Incontinence
  - 3.4.6 Environmental Incontinence (or Functional Incontinence)
  - 3.4.7 Transient Incontinence

Nocturnal Enuresis (Bedwetting)

3.5 How Common is Urinary Incontinence?
- 3.5.1 Around 4% of People in the UK are Incontinent
- 3.5.2 Around 4.5% of People in the US are Incontinent

4. Benign Prostatic Hyperplasia Overview
- 4.1 What is Benign Prostatic Hyperplasia?
- 4.2 The Prostate Gland
- 4.3 Who Does BPH Affect and Why?
- 4.4 What are the Symptoms of BPH?
- 4.5 How Common is BPH?
5. Other Urinary Tract Conditions
- 5.1 Acute Urinary Retention
- 5.2 Cyclophosphamide-Induced Bladder Disorder
6. Treatment Options for Urinary Tract Conditions
- 6.1 Pharmaceutical Therapies for Urinary Incontinence
  - 6.1.1 What Classes of Drugs are Used to Treat Urge Incontinence?
    - 6.1.1.1 Anticholinergics
    - 6.1.1.2 Antispasmodics
    - 6.1.1.3 Alpha-Adrenergic Receptor Blockers
    - 6.1.1.4 Combination Therapy
  - 6.1.2 What Class of Drug is Used to Treat Stress Incontinence?
    - 6.1.2.1 Tricyclic and SNRI Antidepressants
    - 6.1.2.2 Antidepressants Receive FDA Black Box Warning
  - 6.1.3 What Class of Drug is Used to Treat Nocturnal Enuresis?
  - 6.1.4 What Class of Drug is Used to Treat Overactive Bladder?
    - 6.1.4.1 Muscarinic Receptor Antagonists
    - 6.1.4.2 Overactive Bladder Treatments for Children
- 6.2 Behavioural Techniques for Urinary Incontinence
- 6.3 Surgical Treatments for Urinary Incontinence
- 6.4 Pharmaceutical Therapies for Benign Prostatic Hyperplasia and Associated Conditions
  - 6.4.1 Alpha-Blockers
  - 6.4.2 5-Alpha-Reductase Inhibitors
  - 6.4.3 Combination Therapy
- 6.5 Plant Extracts: Non-Pharmaceutical Remedies for BPH
- 6.6 Surgical Treatments for BPH
  - 6.6.1 Minimally Invasive Therapy
    - 6.6.1.1 Transurethral Microwave Procedures
    - 6.6.1.2 Transurethral Needle Ablation
  - 6.6.2 Conventional Surgical Treatment
    - 6.6.2.1 Transurethral Surgery
    - 6.6.2.2 Open Surgery
    - 6.6.2.3 Laser Surgery
- 6.7 Pharmaceutical Treatments for Other Urinary Tract Conditions
7. Unmet Needs in the Urinary Tract Market
- 7.1 Lack of Appropriate Diagnostic Measures
  - 7.1.1 What Diagnosis Methods Exist for BPH?
  - 7.1.2 What is the Prostate Specific Antigen Test and what are its Associated Problems?
- 7.2 Urinary Tract Agent Side Effects
  - 7.2.1 BPH Drugs Cause Sexual Dysfunction
  - 7.2.2 The Market for Overactive Bladder Treatments Needs More Drugs like Enablex
- 7.3 Lack of Treatments for Stress Urinary Intolerance (SUI)
  - 7.3.1 Why do Women Ignore SUI?
  - 7.3.2 How is SUI Traditionally Treated?
    - 7.3.2.1 Pelvic Floor Exercises
    - 7.3.2.2 Vaginal Cones
    - 7.3.2.3 Electronic Devices
    - 7.3.2.4 Elevating Devices
    - 7.3.2.5 Occlusive Devices
    - 7.3.2.6 Surgical Treatment
  - 7.3.3 Yentreve: The Only Existing Pharmaceutical Treatment for SUI
  - 7.3.4 What is the Outlook for Pharmaceutical Treatment of SUI?
    - 7.3.4.1 Roche One of Few Companies with SUI Treatments in Development
    - 7.3.4.2 Sosei and Arachnova Announce Licensing Deal for Clinical Compound in SUI
    - 7.3.4.3 Arachnova Enters Into Data Access And Licensing Deal With Mitsubishi Pharma for Clinical Compound in SUI
8. Emerging Therapies for Urinary Incontinence
- 8.1 Emerging Therapies for Overactive Bladder
  - 8.1.1 Success for Oxytrol in its First Full Year on the Market
  - 8.1.2 Sanctura will Struggle to Gain a Market Foothold
  - 8.1.3 Enablex and Vesicare the Most Promising New Therapies for OAB
    - 8.1.3.1 Enablex Set to Become a Top Three Treatment for OAB
    - 8.1.3.2 Vesicare Unlikely to Trouble Sales of Detrol
    - 8.1.3.3 How will Enablex and Vesicare Position in the Market?
  - 8.1.4 The Pipeline for Overactive Bladder Treatments
    - 8.1.4.1 Fesoterodine Heads a Promising Pipeline for Overactive Bladder Treatments
- 8.2 Emerging Therapies for Stress Urinary Incontinence
- 8.3 Emerging Therapies for Incontinence
9. Emerging Therapies for Benign Prostatic Hyperplasia
- 9.1 Cardura XL Still Awaits Approval for BPH in the US after More than Three Years
- 9.2 Finasteride Awaits Approval for the Japanese Market
- 9.3 GSK Leads the Way in Developing Combination Treatment for BPH
- 9.4 IVAX Have Invented a New Drug for the Treatment of BPH
- 9.5 Few Treatments in The Early Stage Pipeline for BPH
  - 9.5.1 Recordati's Silodosin
  - 9.5.2 QLT Inc.'s QLT0074 (Lemuteporfin)
  - 9.5.3 Nymox Pharma's NX-1207
  - 9.5.4 Solvay's Cetrorelix
10, Emerging Therapies for Other Urinary Tract Disorders
- 10.1 Additional Indications for Existing Therapies willDrive the Market
  - 10.1.1 Yamanouchi's Tamsulosin Seeks LUTS as Additional Indication
  - 10.1.2 Avodart/Avolve Seeks Third Indication
- 10.2 Silodosin Under Development for the Treatment of Dysuria
11. The Market Outlook for Urinary Incontinence Drugs, 2004-2010
- 11.1 The World Incontinence Market Will Reach Nearly $4 Billion by 2010
- 11.2 The Overactive Bladder (OAB) Treatment Revenues Will Exceed $3 Billion by 2010
- 11.3 Detrol for OAB is the World's Largest Selling UI Drug
- 11.4 Detrol Made a Dramatic Recovery in 2004 after Disappointment in 2003
- 11.5 Detrol Will Remain Best Selling UI Drug to 2010
- 11.6 Yentreve: The Only Treatment for SUI Will Become the Second Best Selling UI Drug
12. The Market Outlook fro Benign Prostatic Hyperplasia Drugs, 2004-2010
- 12.1 Patent Expiry is the Major Threat to the BPH Market
- 12.2 The BPH Treatments Market Will See Low Growth After 2006
- 12.3 The World BPH Market Will Be Worth Over $3 Billion by 2010
- 12.4 Flomax and Harnal Dominate the World BPH Market
- 12.5 Flomax has Higher World Sales than Harnal
- 12.6 Nearly Half of all Harnal Sales by Astellas are Outside of Japan
- 12.7 Over 70% of Flomax Sales from Boehringer are in the US
- 12.8 Xatal and Uroxatal Will Generate Revenues of Over $600m by 2010
- 12.9 Avodart Will Generate High Revenues
- 12.10 Proscar Will Suffer Severe Generic Competition
- 12.11 Alpha Blockers Dominate the BPH Market
13. Urinary Tract Market Summary, 2010
- 13.1 The World UTA Market Will See Good Growth to 2010
- 13.2 The OAB Market Will Share Dominance of the UTA Market in 2010
- 13.3 Flomax (tamsulosin) Will Continue to Dominate the UTA Market but at Reduced Market Share
- 13.4 Pfizer is the leading Company in the World UTA Market
- 13.5 Drivers and Restraints in the Urinary Tract Agent Market
14. Conclusion: Growth for the Market will Slow but Remain Positive Beyond the Forecast Period

LIST OF TABLES, GRAPHS AND FIGURES

Table 1.1 Principal Drugs on the UTA Market, 2005

Table 6.1 Pharmaceutical Treatments for Urinary Incontinence and Associated Disorders, 2005

Table 6.2 Drug Treatments for BPH and Associated Conditions, 2005

Table 6.3 Pharmaceutical Treatments for Other Urinary Tract Conditions, 2005

Table 6.4 BPH Treatments and Countries Sold, 2005

Table 6.5 Pharmaceutical Treatments for Other Urinary Tract Conditions, 2005

Table 6.6 Pharmaceutical Treatments for Other Urinary Tract Conditions and Countries Sold, 2005

Table 7.1 Diagnostic Tests for BPH, 2005

Table 7.2 Side-Effects of Selected Urinary Tract Agents for BPH, 2005

Table 7.3 Side-Effects of Urinary Tract Agents for Overactive Bladder, 2005

Table 8.1 Recently Approved Therapies for Overactive Bladder, 2005

Table 8.2 The OAB Pipeline, 2005

Table 8.3 The Stress Urinary Incontinence Pipeline, 2005

Table 8.4 The Incontinence Pipeline, 2005

Table 9.1 The BPH Pipeline, 2005

Table 11.1 Market Share (%) of Different UI Conditions, 2010

Table 11.2 Different Classes of UI Treatments, 2005

Table 11.3 World Revenues ($m) for UI by Condition, 2004-2010

Table 11.4 World Revenues ($m) fro UI Drugs, 2004-2010

Table 11.5 World CAGRs (%) for All UI Drugs, 2004-2010

Table 11.6 World Yentreve Revenues ($m) 2005-2010

Table 12.1 US Patent Expiry Dates for All Drugs in the World BPH Market, 2005

Table 12.2 World Revenues ($m) for Benign Prostatic Hyperplasia Drugs, 2004-2010

Table 12.3 World Market Share (%) for All BPH Drugs, 2004 and 2010

Table 12.4 World Revenues ($m) for Tamsulosin and All Other BPH Drugs, 2004-2010

Table 12.5 World Market Share (%) Tamsulosin and All Other BPH Drugs, 2004-2010

Table 12.6 World Market Share (%) for All BPH Drugs, 2004 and 2010

Table 12.7 World Market Revenues ($m) for All BPH Drugs, 2004 and 2010

Table 12.8 Astellas World Market Revenues ($m) for Harnal by Country region, 2004

Table 12.9 Boehringer World Market Revenues ($m) for Flomax by Country Region, 2004

Table 12.10 World BPH Market Share (%) by Drug Class, 2004 and 2010

Table 13.1 World Revenues ($m) for All Urinary Tract Agents, 2004- 2010

Table 13.2 World UTA Revenues ($m) and CAGR (%), 2004 and 2010

Table 13.3 World UTA Market Share (%) by Disease, 2004 and 2010

Table 13.4 World Revenues ($m) for All UTA Drugs, 2004 and 2010

Table 13.5 World Market Shares (%) for All UTAs, 2004 and 2010

Table 13.6 World UTA Company market Share (%), 2004 and 2010

Table 14.1 World Revenues ($m) for the UTA Market by Indication, 2010

Graph 1.1 The Top Five Urinary Tract Agents, 2003-2004

Graph 7.1 Percentage Discontinuation of BPH Drugs in Clinical Trials Due to Adverse Events, 2004

Graph 7.2 Percentage Discontinuation of OAB Drugs in Clinical Trials Due to Adverse Events, 2004

Graph 11.1 World Revenues ($m) for Indications on the UI Market, 2004 and 2010

Graph 11.2 World Revenues ($m) for UI by Condition, 2004-2010

Graph 11.3 World Detrol Revenues ($m), 2005-2010

Graph 11.4 World Vesicare Revenues ($m), 2005-2010

Graph 11.5 World Yentreve Revenues ($m), 2005-2010

Graph 11.6 World Urinary Incontinence Treatment Revenues ($m), 2010

Graph 12.1 World Revenues ($m) for BPH Drugs, 2004-2010

Graph 12.2 World Avodart/Avolve Revenues ($m), 2005-2010

Graph 12.5 World Proscar Revenues ($m), 2005-2010

Graph 13.1 World Revenues ($m) for Total UTA Market, 2004-2010

Graph 13.2 World Revenues ($m) for the Principal UTA Drugs, 2010

Figure 2.1 The Female Urinary Tract

Figure 2.2 The Male Urinary Tract

Figure 3.1 The Female Bladder and Related Structures

Figure 4.1 The Location of the Prostate Gland

Figure 7.1 Tension Free Vaginal Tape In Situ

Figure 11.1 World Market Share (%) of Different UI Conditions, 2010

Figure 12.1 World Market Share (%) for Tamsulosin and All Other BPH Drugs, 2004

Figure 12.1 World Market Share (%) for Tamsulosin and All Other BPH Drugs, 2010

Figure 13.1 World Market Shares (%) for UTA by Disease, 2010

Figure 13.2 World Market Shares (%) for the Principal Drugs in the UTA Market, 2004

Other users found this report page using the following search terms: incontinence urge incontinence stress incontinence harnal bph flomax market urinary share drugs drug oab tamsulosin

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Urinary Tract Agents Annual Report 2005

Credit Card Details

Invoice Details

Table of Contents